Cargando…

Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression

OBJECTIVE: MicroRNAs (miRs) are class of small non-coding regulatory RNA aberrantly expressed in various types of malignancies including prostate cancer and serves as potential targets to develop new diagnostic and therapeutic strategies. In this quiet we investigated miRNAs expression profile in be...

Descripción completa

Detalles Bibliográficos
Autores principales: Waseem, Mohammad, Ahmad, Mohammad Kaleem, Srivatava, Vikas Kumar, Rastogi, Namrata, Serajuddin, Mohammad, Kumar, Shashank, Mishra, Durga Prasad, Sankhwar, Satya Narain, Mahdi, Abbas Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697479/
https://www.ncbi.nlm.nih.gov/pubmed/28843254
http://dx.doi.org/10.22034/APJCP.2017.18.8.2185
_version_ 1783280632004083712
author Waseem, Mohammad
Ahmad, Mohammad Kaleem
Srivatava, Vikas Kumar
Rastogi, Namrata
Serajuddin, Mohammad
Kumar, Shashank
Mishra, Durga Prasad
Sankhwar, Satya Narain
Mahdi, Abbas Ali
author_facet Waseem, Mohammad
Ahmad, Mohammad Kaleem
Srivatava, Vikas Kumar
Rastogi, Namrata
Serajuddin, Mohammad
Kumar, Shashank
Mishra, Durga Prasad
Sankhwar, Satya Narain
Mahdi, Abbas Ali
author_sort Waseem, Mohammad
collection PubMed
description OBJECTIVE: MicroRNAs (miRs) are class of small non-coding regulatory RNA aberrantly expressed in various types of malignancies including prostate cancer and serves as potential targets to develop new diagnostic and therapeutic strategies. In this quiet we investigated miRNAs expression profile in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue samples and correlated their expression with clinicopathological parameters. METHODOLOGY: The miRNAs expression profile as well as their validation has been done by using Microarray and RT-PCR, respectively. Additionally, we also tried to speculate microRNA-mRNA regulatory module through computational target predictions by using Targetscan, Miranda and MirWalk and obtained results were analysed through DAVID software. RESULT: We observed that miR-711 is significantly deregulated in BPH and PCa, compared to controls. The lower expression of miR-711 was found to be significantly associated with high Gleason score and metastatic disease. Furthermore, the computational target prediction analysis explored miR-711 association to various cancer cells signalling cascade key molecules associated with cancer cell survival. CONCLUSION: From our observations we suggest that miR-711 may play a critical role in PCa progression, regulation of various cancer cell survival signalling cascades and that it may be a valuable biomarker for prediction of metastatic disease and poor prognosis in PCa.
format Online
Article
Text
id pubmed-5697479
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-56974792017-12-01 Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression Waseem, Mohammad Ahmad, Mohammad Kaleem Srivatava, Vikas Kumar Rastogi, Namrata Serajuddin, Mohammad Kumar, Shashank Mishra, Durga Prasad Sankhwar, Satya Narain Mahdi, Abbas Ali Asian Pac J Cancer Prev Research Article OBJECTIVE: MicroRNAs (miRs) are class of small non-coding regulatory RNA aberrantly expressed in various types of malignancies including prostate cancer and serves as potential targets to develop new diagnostic and therapeutic strategies. In this quiet we investigated miRNAs expression profile in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissue samples and correlated their expression with clinicopathological parameters. METHODOLOGY: The miRNAs expression profile as well as their validation has been done by using Microarray and RT-PCR, respectively. Additionally, we also tried to speculate microRNA-mRNA regulatory module through computational target predictions by using Targetscan, Miranda and MirWalk and obtained results were analysed through DAVID software. RESULT: We observed that miR-711 is significantly deregulated in BPH and PCa, compared to controls. The lower expression of miR-711 was found to be significantly associated with high Gleason score and metastatic disease. Furthermore, the computational target prediction analysis explored miR-711 association to various cancer cells signalling cascade key molecules associated with cancer cell survival. CONCLUSION: From our observations we suggest that miR-711 may play a critical role in PCa progression, regulation of various cancer cell survival signalling cascades and that it may be a valuable biomarker for prediction of metastatic disease and poor prognosis in PCa. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5697479/ /pubmed/28843254 http://dx.doi.org/10.22034/APJCP.2017.18.8.2185 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
Waseem, Mohammad
Ahmad, Mohammad Kaleem
Srivatava, Vikas Kumar
Rastogi, Namrata
Serajuddin, Mohammad
Kumar, Shashank
Mishra, Durga Prasad
Sankhwar, Satya Narain
Mahdi, Abbas Ali
Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title_full Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title_fullStr Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title_full_unstemmed Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title_short Evaluation of miR-711 as Novel Biomarker in Prostate Cancer Progression
title_sort evaluation of mir-711 as novel biomarker in prostate cancer progression
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697479/
https://www.ncbi.nlm.nih.gov/pubmed/28843254
http://dx.doi.org/10.22034/APJCP.2017.18.8.2185
work_keys_str_mv AT waseemmohammad evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT ahmadmohammadkaleem evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT srivatavavikaskumar evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT rastoginamrata evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT serajuddinmohammad evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT kumarshashank evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT mishradurgaprasad evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT sankhwarsatyanarain evaluationofmir711asnovelbiomarkerinprostatecancerprogression
AT mahdiabbasali evaluationofmir711asnovelbiomarkerinprostatecancerprogression